Her primary areas of investigation include Virology, Plasmodium falciparum, Antibody, Antigen and Malaria. Carole A. Long interconnects Immunology, Immune system, Immunogenicity and Parasitemia in the investigation of issues within Virology. Carole A. Long has researched Plasmodium falciparum in several fields, including Immunoglobulin G, Immunity and Microbiology.
Her Antibody research integrates issues from Heterologous and Plasmodium yoelii. Her Antigen research includes themes of Neutralizing antibody, Monoclonal antibody and Recombinant DNA. In general Malaria study, her work on Apicomplexa and Plasmodium vivax often relates to the realm of Basigin, thereby connecting several areas of interest.
Her primary scientific interests are in Plasmodium falciparum, Virology, Antigen, Antibody and Immunology. Her Plasmodium falciparum study incorporates themes from Recombinant DNA and Vaccination. Her Virology study integrates concerns from other disciplines, such as Immune system, Immunity, Immunogenicity, Plasmodium yoelii and Epitope.
Her Antigen research is multidisciplinary, relying on both T cell, Molecular biology, Monoclonal antibody and Microbiology. Her work on Immunoglobulin G, Antibody titer and Immunization as part of her general Antibody study is frequently connected to Merozoite surface protein, thereby bridging the divide between different branches of science. Her work in the fields of Adjuvant, Parasitemia, Acquired immune system and Humoral immunity overlaps with other areas such as CpG site.
Carole A. Long focuses on Antibody, Plasmodium falciparum, Antigen, Malaria and Virology. Her Antibody research is multidisciplinary, incorporating perspectives in Molecular biology and Malaria vaccine. Her work deals with themes such as Parasitology, Monoclonal antibody, Immunization and Recombinant DNA, which intersect with Plasmodium falciparum.
In the subject of general Antigen, her work in Immunogenicity is often linked to Monophosphoryl Lipid A, thereby combining diverse domains of study. The various areas that Carole A. Long examines in her Malaria study include Interquartile range and Arbitrary unit. Her studies deal with areas such as Endemic area, Transmission blocking and Sterility as well as Virology.
Carole A. Long mainly investigates Antibody, Plasmodium falciparum, Malaria, Antigen and Virology. Her Antibody research focuses on Recombinant DNA and how it connects with Adjuvant, Bivalent, Immunofluorescence and Molecular biology. Her Plasmodium falciparum research is multidisciplinary, incorporating elements of Internal medicine, Interquartile range, Gastroenterology, Blot and Serology.
Her research investigates the connection between Malaria and topics such as Immune system that intersect with problems in Plasmodium berghei. Her Antigen research is multidisciplinary, relying on both Liposome and Immunity. Her Virology study combines topics in areas such as Malaria vaccine and Monoclonal antibody.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Erratum: Corrigendum: The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
A D Douglas;A R Williams;J J Illingworth;G Kamuyu.
Nature Communications (2013)
Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
Yimin Wu;Ruth D. Ellis;Donna Shaffer;Erica Fontes.
PLOS ONE (2008)
In Vitro Studies with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 (AMA1): Production and Activity of an AMA1 Vaccine and Generation of a Multiallelic Response
Michael C. Kennedy;Jin Wang;Yanling Zhang;Aaron P. Miles.
Infection and Immunity (2002)
Phase 1 Clinical Trial of Apical Membrane Antigen 1: an Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
Elissa M. Malkin;David J. Diemert;Julie H. McArthur;John R. Perreault.
Infection and Immunity (2005)
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.
Elissa M. Malkin;Anna P. Durbin;David J. Diemert;Jetsumon Sattabongkot.
The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody
Alexander D. Douglas;Andrew R. Williams;Joseph J. Illingworth;Gathoni Kamuyu.
Nature Communications (2011)
Vaccination of Monkeys with Recombinant Plasmodium falciparum Apical Membrane Antigen 1 Confers Protection against Blood-Stage Malaria
Anthony W. Stowers;Michael C. Kennedy;Brian P. Keegan;Allan Saul.
Infection and Immunity (2002)
Passive immunization against murine malaria with an IgG3 monoclonal antibody.
W R Majarian;T M Daly;W P Weidanz;C A Long.
Journal of Immunology (1984)
Immunity to Recombinant Plasmodium falciparum Merozoite Surface Protein 1 (MSP1): Protection in Aotus nancymai Monkeys Strongly Correlates with Anti-MSP1 Antibody Titer and In Vitro Parasite-Inhibitory Activity
Sanjay Singh;Kazutoyo Miura;Hong Zhou;Olga Muratova.
Infection and Immunity (2006)
Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A
Michele D. Spring;James F. Cummings;Christian F. Ockenhouse;Sheetij Dutta.
PLOS ONE (2009)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: